9-ING-41 in Patients With Advanced Cancers (NCT03678883)
Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3ฮฒ) Inhibitor, as a Single Agent and Combined With Chemotherapy, in Patients With Refractory Hematologic Malignancies or Solid Tumors
๐ฉบ Plain-English Summary (8th-Grade Level)
GSK-3ฮฒ is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3ฮฒ inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers.
Who can join: Review the eligibility criteria below.
Location: Mayo Clinic โ Phoenix, Arizona
Age range: 18 Years
๐งช Interventions in This Study
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (66 Sites)
Showing the first 25 of 66 sites.
- Mayo Clinic โ Phoenix, Arizona
- Arizona Oncology Associates โ Tucson, Arizona
- The University of Arizona Cancer Center โ Tucson, Arizona
- University of California Irvine Health โ Orange, California
- UCSF Helen Diller Family Comprehensive Cancer Center โ San Francisco, California
- Christiana Care Health Services โ Newark, Delaware
- Sibley Memorial Hospital โ Washington D.C., District of Columbia
- Florida Cancer Specialists - South โ Fort Myers, Florida
- Miami Cancer Institute โ Miami, Florida
- Florida Cancer Specialists - North โ St. Petersburg, Florida
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University โ Chicago, Illinois
- Des Moines Oncology Research Association โ Des Moines, Iowa
- Kansas University Cancer Center โ Kansas City, Kansas
- Ochsner Clinic Foundation โ New Orleans, Louisiana
- University of Michigan โ Ann Arbor, Michigan
- MetroMetro-Minnesota Community Oncology Research Consortium (MMCORC) โ Minneapolis, Minnesota
- Mayo Clinic โ Rochester, Minnesota
- Comprehensive Cancer Centers of Nevada โ Las Vegas, Nevada
- Morristown Medical Center โ Morristown, New Jersey
- Capital Health Medical Center/ Hopewell โ Pennington, New Jersey
- MD Anderson Cancer Center at Cooper โ Voorhees Township, New Jersey
- Columbia University- Irving Medical Center โ New York, New York
- Stony Brook University Hospital โ Stony Brook, New York
- Duke University Medical Center โ Durham, North Carolina
- Oregon Health and Science University โ Portland, Oregon
๐ Contact the Study Coordinator
Phone: (800) 664-4580
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Cancer
- Ovarian Tissue Cryopreservation in Children โ Rochester, Minnesota
- A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study โ Aurora, Colorado
- Ex Onc SLED: A Study Utilizing A Weighted Sled for Horizontal Resistance Training โ Pittsburgh, Pennsylvania
- An Internet-based Program to Help Cancer Survivors Manage Pain โ Fort Smith, Arkansas
- Identification of Patients With Age-Related Clonal Hematopoiesis (ARCH) Among Cancer Survivors โ Toronto, Ontario
- Researching the Effect of Aerobic Exercise on Cancer โ Los Angeles, California
Explore by condition: All Cancer clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.